Fujimasa Tada
A5083997418- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Pancreatitis Pathology and Treatment
- Nutrition and Health in Aging
- Liver physiology and pathology
- Cancer Mechanisms and Therapy
- Liver Diseases and Immunity
- Renal cell carcinoma treatment
- Adipokines, Inflammation, and Metabolic Diseases
- Gastric Cancer Management and Outcomes
- Diet, Metabolism, and Disease
- Neuroendocrine Tumor Research Advances
- Immune Cell Function and Interaction
- Endoplasmic Reticulum Stress and Disease
- Diabetes and associated disorders
- Lung Cancer Research Studies
- Alcohol Consumption and Health Effects
Ehime Prefectural Central Hospital
2022-2025
Himeji University
2024
Ehime University
2011-2023
National Hospital Organization Takasaki Medical Center
2023
Saiseikai Matsuyama Hospital
2017-2023
Kagawa Prefectural Central Hospital
2023
Nippon Medical School
2023
AstraZeneca (Brazil)
2023
Bayer (Finland)
2023
Gifu Kyoritsu University
2023
Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however, there has been very little development in DC vaccines patients with hepatocellular carcinoma (HCC). In this study, we assessed the safety, feasibility and efficacy of a multiple tumor-associated antigen (TAA)-pulsed vaccine 5 advanced HCC. DCs were generated by culturing blood monocytes presence granulocyte macrophage-colony stimulating factor interleukin-4 days. The was prepared pulsing cytoplasmic...
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total 1381 had PD at therapy. 917 received as treatment, 464 bevacizumab first-line.49.6% a therapy without any statistical difference in overall survival (OS) between (20.6months) (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After first-line, there wasn't...
Introduction: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is important clinical issue. The present study aimed to elucidate the potential lenvatinib as a second-line option after Atez/Bev failure. Methods: From 2020 2022, 101 patients who received were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D = 1:35:61:4), while 29 treated with another molecular targeting agent (MTA)...
Background/Aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use tumor markers as biomarkers monitoring treatment response is necessary. This study aimed to elucidate changes positive rates 3 available Japan, including alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and lens culinaris agglutinin-reactive AFP (AFP-L3) uHCC...
The aim of this study was to prospectively measure liver stiffness with real-time tissue elastography in patients nonalcoholic fatty diseases (NAFLD) and compare the result clinical assessment fibrosis using histological stage. One hundred eighty-one enrolled underwent elastography, first 106 being analyzed as training set remaining 75 evaluated validation set. Hepatic splenic elastic ratios were calculated compared stage fibrosis. Portal hypertension (PH) assessed. Real-time cut-off values...
Aim The predictors for the development of hepatocellular carcinoma (HCC) after direct‐acting antiviral (DAA) treatment were investigated. Methods A total 1174 patients with chronic hepatitis C virus infection treated DAA therapy (sofosbuvir and ledipasvir [ n = 615], sofosbuvir ribavirin 380], daclatasvir asunaprevir 179]) achieved sustained virologic response (SVR). HCC rate factors that might contribute to end analyzed. Results During median observation period 537 days, developed in 33...
The present study focused on Geriatric Nutritional Risk Index (GNRI), which is based bodyweight and serum albumin, known as an easy-to-use nutritional assessment tool in clinical settings, to elucidate the prognostic predictive ability of GNRI patients treated with atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC).A total 525 HCC Atez/Bev, their classification unsuitable status curative treatments and/or transarterial catheter chemoembolization, were enrolled...
Lenvatinib is used to treat advanced hepatocellular carcinoma (HCC). Metabolic dysfunction-associated fatty liver disease (MAFLD) becoming a major etiology of HCC. We aimed evaluate the impact MAFLD on efficacy lenvatinib.We enrolled 320 patients with HCC who were treated lenvatinib. All classified into (n = 155) and non-MAFLD 165) groups. Independent factors for overall survival (OS) analyzed. In stratification analysis, was categorized as non-viral 115) or viral 205).The OS rate...
Recently, the neo-Glasgow prognostic score (GPS), a composite biomarker determined by C-reactive protein level and albumin-bilirubin grade, was developed to predict outcomes in hepatocellular carcinoma (HCC) patients who undergo hepatic resection. The present research investigated whether neo-GPS could prognosis HCC treated with atezolizumab plus bevacizumab (Atez/Bev).A total of 421 were Atez/Bev investigated.Multivariate Cox hazards analysis showed that GPS 1 (hazard ratio (HR), 1.711; 95%...
Introduction: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its role has been shown treated sorafenib lenvatinib. aim this real-world study was to investigate association between clinical outcomes PNI being atezolizumab plus bevacizumab. Methods: overall cohort multicentric included 871 consecutive HCC from 5...
Abstract Aims The aim of the present study was to elucidate detailed parameters for prediction prognosis patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total 719 (males 577, median age 74 years) treated Atez/Bev between September 2020 and January 2023 were enrolled. Factors related overall survival (OS) extracted a prognostic scoring system based on hazard ratio (HR) created. OS progression‐free (PFS)...
The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses IMbrave-150 metanalyses clinical trials PD-1/PD-L1 blockers. As a results, it not clear whether the first-line systemic treatment atezolizumab plus bevacizumab (A + B) equally effective viral nonviral patients.
Visceral adipose tissue (VAT) inflammation has been linked to the pathogenesis of insulin resistance and metabolic syndrome. VAT recently established as a new component immune system is involved in production various adipokines cytokines. These molecules contribute inducing accelerating systemic resistance. In this report, we investigated role B cell-activating factor (BAFF) induction We BAFF levels sera obese mice. mice, were preferentially increased compared these normal control Next,...
There are few effective medications for non-alcoholic steatohepatitis (NASH). We investigated the efficacy of ipragliflozin (selective sodium-glucose cotransporter-2 inhibitor [SGLT2I]) treatment patients with type 2 diabetes mellitus (T2DM) complicated by fatty liver disease (NAFLD).We prospectively enrolled T2DM NAFLD treated at our institutions from January 2015 to December 2016. Patients received oral (50 mg/day) once daily 24 weeks. Body composition was evaluated using an InBody720...
It is not uncommon to encounter outpatients in the hepatology department with harmful alcohol habits. When treating such chronic liver disease (CLD) patients, an adequate intervention method for harm reduction of use, as brief (BI) or BI and nalmefene, should be considered. This study aimed elucidate clinical effectiveness CLD patients affected by use.
This study aimed to compare the prognostic performance of risk models for patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atez/Bev) as first-line treatment. Among 449 included in this retrospective multicenter study, we compared 13 12-month 18-month survival status using area under curve (AUC), net reclassification improvement (NRI), relative integrated discrimination (IDI) analysis. We also constructed a calibration plot assess fitness each model....
ABSTRACT Aim This study aims to investigate the clinical utility of derived neutrophil‐to‐lymphocyte ratio (dNLR) and Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable hepatocellular carcinoma (HCC) undergoing combination therapy atezolizumab bevacizumab (Atez/Bev). Methods A retrospective analysis was conducted on 310 patients. The dNLR, NLR, GNRI were calculated, their impact progression‐free survival (PFS) overall (OS) assessed....